Cognitive Diagnostics Market Report 2026

The cognitive diagnostics market size has grown exponentially in recent years. It will grow from $6.25 billion in 2025 to $7.69 billion in 2026 at a compound annual growth rate (CAGR) of 23.1%. The growth in the historic period can be attributed to growing prevalence of neurodegenerative disorders, increasing awareness of cognitive health, expansion of diagnostic imaging capabilities, rising adoption of standardized cognitive tests, growth in neurology specialty clinics.

The cognitive diagnostics market size is expected to see exponential growth in the next few years. It will grow to $17.46 billion in 2030 at a compound annual growth rate (CAGR) of 22.7%. The growth in the forecast period can be attributed to increasing investments in digital diagnostics, rising demand for early-stage cognitive disorder detection, expansion of home-based cognitive assessment tools, growing integration of ai in clinical decision support, increasing focus on personalized cognitive care. Major trends in the forecast period include increasing use of AI-based cognitive assessment tools, rising adoption of digital cognitive screening platforms, growing deployment of neuroimaging analytics, expansion of remote cognitive testing solutions, enhanced focus on early disease detection.

The rising prevalence of neurological disorders is expected to drive the growth of the cognitive diagnostics market in the coming years. Neurological disorders are conditions affecting the brain, spinal cord, and nervous system, leading to symptoms such as cognitive decline, motor dysfunction, and sensory impairments. The increase in these disorders is fueled by age-related conditions like Alzheimer’s and Parkinson’s disease, as well as hereditary factors, environmental toxins, stress, unhealthy diets, and sedentary lifestyles. Cognitive diagnostics play a key role in assessing, detecting, and monitoring cognitive impairments, supporting early diagnosis and management of diseases such as Alzheimer’s and Parkinson’s. For example, in May 2024, the Alzheimer’s Association, a US-based nonprofit organization, reported that the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia rose from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the rising incidence of neurological disorders is driving the cognitive diagnostics market.

Leading companies in the cognitive diagnostics market are focusing on providing real-time insights into cognitive health through advanced diagnostic tools, such as neuropsychological testing platforms, to improve accuracy, efficiency, and comprehensiveness in cognitive assessments. Neuropsychological testing platforms are digital tools designed to evaluate cognitive functions through standardized tests assessing memory, attention, problem-solving, and other skills. For instance, in April 2024, BrainCheck Inc., a US-based digital health company, launched its comprehensive digital cognitive assessment platform at the American Academy of Neurology (AAN) Annual Meeting. The platform, which includes Assess, Screen, and Plan modules, offers clinicians a modern solution for cognitive screening, assessment, and care planning using mobile, digital technology, ensuring accuracy and ease of use. This innovation enhances care efficiency and quality by providing evidence-based recommendations and comprehensive planning for patients and providers.

In July 2024, Lantheus Holdings, Inc., a US-based radiopharmaceutical company, acquired Meilleur Technologies Inc. for an undisclosed amount. This acquisition strengthens Lantheus’s Alzheimer’s diagnostic portfolio by combining Meilleur’s NAV-4694, which detects beta-amyloid plaques, with Lantheus’ existing PET agent MK-6240 for tau tangles. The combined offering provides a comprehensive diagnostic solution for Alzheimer’s disease, supporting both early detection and monitoring of disease-modifying treatments. Meilleur Technologies Inc. specializes in developing radiopharmaceutical diagnostics for cognitive conditions.

Major companies operating in the cognitive diagnostics market are Cogstate Ltd., Viz.ai, Redcliffe Labs, Mind Maze, Neurocare Group AG, Pathway Genomics, Diadem srl, Cambridge Cognition Ltd., Posit Science Corporation, Anderson Diagnostics & Labs., Altoida AG, BrainScope Company Inc., Neurotrack Technologies Inc., Cognetivity Neurosciences Ltd., BrainCheck, Cyclops MedTech Pvt Ltd, Twill Inc., CN Diagnostics, Savonix Inc., Cognivue Inc., NeuroCog Trials, Pearson Clinical, Re:Cognition Health, CogniSense, The Neuropsychology Consultants.

North America was the largest region in the cognitive diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cognitive diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cognitive diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the cognitive diagnostics market by raising costs of imported imaging equipment, advanced sensors, diagnostic software systems, and specialized electronic components used in cognitive assessment tools. Hospitals and diagnostic centers in North America and Europe are most affected due to dependence on imported high-end imaging and analytics technologies, while Asia-Pacific faces pricing pressure on device manufacturing and exports. These tariffs are increasing diagnostic system costs and slowing equipment upgrades. At the same time, they are encouraging local software development, regional manufacturing of diagnostic devices, and greater adoption of cloud-based cognitive assessment platforms.

The cognitive diagnostics market research report is one of a series of new reports that provides cognitive diagnostics market statistics, including cognitive diagnostics industry global market size, regional shares, competitors with a cognitive diagnostics market share, detailed cognitive diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cognitive diagnostics industry. This cognitive diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cognitive diagnostics refers to the assessment and evaluation of an individual’s cognitive functions to identify and understand cognitive disorders or impairments. This field focuses on detecting issues related to memory, attention, language, problem-solving, and other cognitive abilities. It employs a range of methods and tools to analyze cognitive performance and determine the presence of conditions such as dementia, Alzheimer’s disease, traumatic brain injury, or other cognitive impairments.

The main types of cognitive diagnostics include brain imaging tests, laboratory testing, mental status testing, rapid home screening tests, neuropsychological testing, electroencephalograms (EEG), cognitive and behavioral tests, and the Neuropsychiatric Inventory Questionnaire (NPI-Q). Brain imaging tests, such as MRI and CT scans, are used to visualize the brain’s structure and function to detect abnormalities or changes indicative of cognitive disorders. Indications include Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), dementia, epilepsy-related cognitive dysfunction, mild cognitive impairment, Parkinson’s disease-related cognitive dysfunction, stroke-related cognitive dysfunction, traumatic brain injury, and others. End users of cognitive diagnostics include hospitals, neurology clinics, cognitive behavioral therapy centers, rehabilitation centers, academic and research institutes, diagnostic imaging centers, and home care settings.

The cognitive diagnostics market consists of revenues earned by entities by providing services such as consultation services, rehabilitation services, and therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cognitive diagnostics market also includes sales of cognitive assessment software, neuropsychological testing kits, smartwatches and wearables with cognitive monitoring capabilities, and brain training software and apps. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.